Scientists Uncover How Head and Neck Cancers Evade Immune System, Offering New Treatment Hope

Scientists at Henry Ford Health + Michigan State University Health Sciences have identified a mechanism that allows specific head and neck cancers to evade the immune system. This discovery, detailed in Proceedings of the National Academy of Sciences (PNAS), pinpoints a protein involved in this process, suggesting new approaches for treating resistant tumors.

Mechanism of Immune Evasion

For an extended period, medical professionals have observed that Human Papillomavirus (HPV)-associated head and neck cancers lack MHCI molecules. These are critical markers cells use to signal distress to the immune system. Without these markers, the immune system does not recognize the cancerous cells.

The research team, led by Dr. Dohun Pyeon, professor in the Department of Microbiology, Genetics, & Immunology, demonstrated that HPV utilizes a protein named MARCHF8 to dismantle these MHCI markers before the immune system can detect the cancer cells.

Impact of MARCHF8 Removal

In experimental models, the removal of MARCHF8 resulted in the immune system initiating the clearance of tumors. This occurred even in instances where standard immunotherapy had previously been ineffective.

The absence of MARCHF8 allowed immune cells, including CD8+ T cells and natural killer cells, to enter the tumor microenvironment, thereby re-establishing an immune response.

Dr. Pyeon noted that this approach was effective on tumors previously resistant to treatment. He suggested that combining this genetic intervention with existing immunotherapy drugs could transform patient outcomes.